Lyra Therapeutics, Inc. financial data

Symbol
LYRA on Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
Location
480 Arsenal Way, Watertown, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
480 Biomedical, Inc. (to 11/28/2016), Arsenal Vascular, Inc. (to 11/8/2011), Arsenal Medical, Inc. (to 8/12/2010), WMR Biomedical Inc (to 2/27/2009)
Latest financial report
10-K - Q4 2024 - Mar 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 391 % -36.5%
Debt-to-equity 171 % +301%
Return On Equity -266 % -258%
Return On Assets -98 % -88.8%
Operating Margin -6.28K % -45.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 65.9M shares +8.06%
Common Stock, Shares, Outstanding 65.5M shares +14.5%
Entity Public Float 13.8B USD -90.4%
Common Stock, Value, Issued 65K USD +14%
Weighted Average Number of Shares Outstanding, Basic 65.1M shares +30.7%
Weighted Average Number of Shares Outstanding, Diluted 65.1M shares +30.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.53M USD -1.54%
Research and Development Expense 43.8M USD -8.88%
General and Administrative Expense 18.5M USD -2.92%
Operating Income (Loss) -96.3M USD -43.5%
Nonoperating Income (Expense) 2.95M USD -34.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -93.4M USD -49.1%
Income Tax Expense (Benefit) 39K USD -33.9%
Net Income (Loss) Attributable to Parent -93.4M USD -49.1%
Earnings Per Share, Basic -1.43 USD/shares -13.5%
Earnings Per Share, Diluted -1.43 USD/shares -13.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 40.6M USD +81.5%
Assets, Current 43M USD -59%
Property, Plant and Equipment, Net 1.4M USD -31.3%
Operating Lease, Right-of-Use Asset 19.9M USD -40%
Other Assets, Noncurrent 0 USD -100%
Assets 66.3M USD -53.5%
Accounts Payable, Current 1.18M USD -62.3%
Employee-related Liabilities, Current 529K USD -88.7%
Liabilities, Current 12.6M USD -35.5%
Operating Lease, Liability, Noncurrent 30.3M USD +41.1%
Liabilities 54.8M USD +2.96%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD -100%
Retained Earnings (Accumulated Deficit) -405M USD -30%
Stockholders' Equity Attributable to Parent 11.6M USD -87%
Liabilities and Equity 66.3M USD -53.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.5M USD -41.7%
Net Cash Provided by (Used in) Financing Activities 8.64M USD
Net Cash Provided by (Used in) Investing Activities 7.86M USD +47.8%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 65.5M shares +14.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.95M USD +43.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 42.6M USD +79.3%
Deferred Tax Assets, Valuation Allowance 84.8M USD +41.5%
Deferred Tax Assets, Gross 88.5M USD +31.5%
Operating Lease, Liability 34.4M USD +27.9%
Depreciation 136K USD -52.1%
Payments to Acquire Property, Plant, and Equipment 2.15M USD +4676%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -93.5M USD -49.2%
Lessee, Operating Lease, Liability, to be Paid 42.9M USD +26%
Property, Plant and Equipment, Gross 5.53M USD +39.6%
Operating Lease, Liability, Current 4.12M USD -24.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.49M USD +51.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.12M USD -17.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8.53M USD +18.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.13M USD +11.7%
Deferred Tax Assets, Operating Loss Carryforwards 41.3M USD +37.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.51M USD +42%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 3.74M USD -49.4%
Share-based Payment Arrangement, Expense 6.72M USD +14.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%